(1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study.

A treatment strategy for patients in the ICU at high risk for candidaemia showed that the results of testing for (1,3)-beta-d-glucan could be used for starting, as well as stopping, antifungal therapy.To determine the effects of a strategy that uses serum (1,3)-beta-d-glucan (BDG) results for antifungal treatment of ICU patients at high risk of invasive candidiasis. Adult patients admitted to the ICU from January 2012 to June 2014 were included if they exhibited sepsis at the time of BDG testing and they met Candida score components a parts per thousand yen3. A retrospective analysis of collected data was performed. In total, 198 patients were studied. Of 63 BDG-positive patients, 47 with candidaemia and 16 with probable Candida infection, all [31.8% (63/198)] received antifungal therapy. Of 135 BDG-negative patients, 110 [55.5% (110/198)] did not receive antifungal therapy, whereas 25 [12.6% (25/198)] were initially treated. Overall, antifungal therapy was started in 88 cases (44.4%), mostly with echinocandins. Antifungals were discontinued in 14 of 25 patients, as negative BDG results became available, and in 16 BDG-false-positive patients for whom subsequent findings allowed candidaemia (and other forms of invasive candidiasis) to be ruled out. Candidaemia was diagnosed only in one patient who did not receive prior antifungal therapy. The median antifungal therapy duration in candidaemic patients differed significantly from that in non-candidaemic patients [14 (IQR, 6-18) days versus 4 (IQR, 3-7) days; PaEuroS < aEuroS0.001]. Using this approach, antifungal therapy was avoided in similar to 73% of potentially treatable patients and it was shortened in another similar to 20%. This study supports the use of serum BDG results in the management of systemic antifungal drug prescription in septic patients. These findings need to be confirmed in additional studies.